- Home
- PCRX vs AWF Comparison
PCRX vs AWF Comparison
Compare PCRX & AWF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- AWF
- Stock Information
- Founded
- PCRX 2006
- AWF 1993
- Country
- PCRX United States
- AWF United States
- Employees
- PCRX N/A
- AWF N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- AWF Trusts Except Educational Religious and Charitable
- Sector
- PCRX Health Care
- AWF Finance
- Exchange
- PCRX Nasdaq
- AWF Nasdaq
- Market Cap
- PCRX 1.2B
- AWF 928.7M
- IPO Year
- PCRX 2011
- AWF N/A
- Fundamental
- Price
- PCRX $25.12
- AWF $10.65
- Analyst Decision
- PCRX Buy
- AWF
- Analyst Count
- PCRX 9
- AWF 0
- Target Price
- PCRX $29.89
- AWF N/A
- AVG Volume (30 Days)
- PCRX 782.0K
- AWF 190.0K
- Earning Date
- PCRX 05-08-2025
- AWF 01-01-0001
- Dividend Yield
- PCRX N/A
- AWF 7.57%
- EPS Growth
- PCRX N/A
- AWF N/A
- EPS
- PCRX N/A
- AWF N/A
- Revenue
- PCRX $702,772,000.00
- AWF N/A
- Revenue This Year
- PCRX $9.48
- AWF N/A
- Revenue Next Year
- PCRX $11.31
- AWF N/A
- P/E Ratio
- PCRX N/A
- AWF N/A
- Revenue Growth
- PCRX 3.08
- AWF N/A
- 52 Week Low
- PCRX $11.16
- AWF $9.20
- 52 Week High
- PCRX $31.67
- AWF $10.67
- Technical
- Relative Strength Index (RSI)
- PCRX 48.10
- AWF 58.82
- Support Level
- PCRX $25.08
- AWF $10.52
- Resistance Level
- PCRX $27.34
- AWF $10.63
- Average True Range (ATR)
- PCRX 1.16
- AWF 0.09
- MACD
- PCRX -0.18
- AWF 0.04
- Stochastic Oscillator
- PCRX 48.85
- AWF 99.15
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About AWF Alliancebernstein Global High Income Fund
Alliancebernstein Glb High Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its primary investment objective is to seek high current income, and secondarily, capital appreciation. The fund invests in the debt securities, including Sovereign Debt Obligations and corporate debt, denominated in non-U.S. currencies as well as in the U.S. Dollar. It may invest without limit in emerging and developed markets and debt securities of U.S. and non-U.S. corporate issuers.